Establishment of a novel identification system for Enterotoxigenic Bacteroides fragilis using CRISPR-Cas13 and bacteriophage technology

点击翻译按钮获取中文摘要

Enterotoxigenic Bacteroides fragilis (ETBF) is the cause of inflammatory diarrhea of the colon and intestinal cancer. 5-20% of the world's population carries this strain asymptomatically. Therefore, rapid and easy detection methods are needed to properly prevent and treat the disease. Our laboratory has independently developed an antibacterial capsid using the CRISPR-Cas13a system. This application aims to establish a simple identification system using the bft gene of Bacteroides fragilis. This study culminates in the development of new therapeutic strategies for controlling gut microbiota in the gut microbiota community.In the first year, I have achieved some results: I collected 215 Bacteroides fragilis (BF) strains, including 12 bft1-positive, 8 bft-2-positive, and 1 bft-3-positive strain. I performed whole-genome sequencing on 50 strains, completing a comprehensive survey of their genomes and found out 11 strains revealed prophage sequences in their genome. Based on the results of MIC, six strains that susceptible to antibiotics and not carry prophage in their genome, were suitable to carry Capsid.